FDMT - 4D Molecular Therapeutics Inc

4D Molecular Therapeutics, Inc. is a clinical-stage biotherapeutics company that leverages its innovative therapeutic vector evolution platform to develop genetic medicines. With operations in the Netherlands and the United States, the company is dedicated to creating a portfolio of product candidates that address unmet medical needs in three key therapeutic areas: ophthalmology, cardiology, and pulmonology.

The company's product pipeline is robust, with several candidates in various stages of clinical development. 4D-150, for instance, is being evaluated in phase 1/2 clinical trials for the treatment of wet age-related macular degeneration and diabetic macular edema. Meanwhile, 4D-125 is being developed to treat x-linked retinitis pigmentosa, and 4D-110 is being investigated for the treatment of choroideremia. Additionally, 4D-710 is being developed to treat cystic fibrosis lung disease, and 4D-310 is being explored for the treatment of Fabry disease cardiomyopathy. All of these candidates are currently in phase 1/2 clinical trials.

Beyond its clinical-stage candidates, 4D Molecular Therapeutics also has several pre-clinical programs in development. 4D-175, for example, is being developed to treat geographic atrophy, while 4D-725 is being investigated for the treatment of alpha-1 antitrypsin deficiency lung disease. The company's commitment to innovation and collaboration is evident in its partnerships with leading organizations such as Arbor Biotechnologies, Inc., Astellas Gene Therapies, Inc., uniQure biopharma B.V., and the Cystic Fibrosis Foundation.

Founded in 2013, 4D Molecular Therapeutics, Inc. is headquartered in Emeryville, California, and is poised to make a significant impact in the field of genetic medicine. With its cutting-edge platform and robust product pipeline, the company is well-positioned to address some of the most pressing unmet medical needs of our time.